Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling

Mitsunobu Kano, Younsoo Bae, Caname Iwata, Yasuyuki Morishita, Masakazu Yashiro, Masako Oka, Tomoko Fujii, Akiyoshi Komuro, Kunihiko Kiyono, Michio Kaminishi, Kosei Hirakawa, Yasuyoshi Ouchi, Nobuhiro Nishiyama, Kazunori Kataoka, Kohei Miyazono

Research output: Contribution to journalArticle

306 Citations (Scopus)

Abstract

Transforming growth factor (TGF)-β plays a pivotal role in regulation of progression of cancer through effects on tumor microenvironment as well as on cancer cells. TGF-β inhibitors have recently been shown to prevent the growth and metastasis of certain cancers. However, there may be adverse effects caused by TGF-β signaling inhibition, including the induction of cancers by the repression of TGF-β-mediated growth inhibition. Here, we present an application of a short-acting, small-molecule TGF-β type I receptor (TβR-I) inhibitor at a low dose in treating several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer, characterized by hypovascularity and thick fibrosis in tumor microenvironments. Low-dose TβR-I inhibitor altered neither TGF-β signaling in cancer cells nor the amount of fibrotic components. However, it decreased pericyte coverage of the endothelium without reducing endothelial area specifically in tumor neovasculature and promoted accumulation of macromolecules, including anticancer nanocarriers, in the tumors. Compared with the absence of TβR-I inhibitor, anticancer nanocarriers exhibited potent growth-inhibitory effects on these cancers in the presence of TβR-I inhibitor. The use of TβR-I inhibitor combined with nanocarriers may thus be of significant clinical and practical importance in treating intractable solid cancers.

Original languageEnglish
Pages (from-to)3460-3465
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume104
Issue number9
DOIs
Publication statusPublished - Feb 27 2007
Externally publishedYes

Fingerprint

Transforming Growth Factors
Neoplasms
Therapeutics
Tumor Microenvironment
Growth
Growth Inhibitors
Pericytes
Growth Factor Receptors
Stomach Neoplasms
Endothelium
Adenocarcinoma
Fibrosis
Neoplasm Metastasis

Keywords

  • Angiogenesis
  • Gastric cancer
  • Molecular targeting therapy
  • Pancreatic cancer

ASJC Scopus subject areas

  • Genetics
  • General

Cite this

Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. / Kano, Mitsunobu; Bae, Younsoo; Iwata, Caname; Morishita, Yasuyuki; Yashiro, Masakazu; Oka, Masako; Fujii, Tomoko; Komuro, Akiyoshi; Kiyono, Kunihiko; Kaminishi, Michio; Hirakawa, Kosei; Ouchi, Yasuyoshi; Nishiyama, Nobuhiro; Kataoka, Kazunori; Miyazono, Kohei.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 104, No. 9, 27.02.2007, p. 3460-3465.

Research output: Contribution to journalArticle

Kano, M, Bae, Y, Iwata, C, Morishita, Y, Yashiro, M, Oka, M, Fujii, T, Komuro, A, Kiyono, K, Kaminishi, M, Hirakawa, K, Ouchi, Y, Nishiyama, N, Kataoka, K & Miyazono, K 2007, 'Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling', Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 9, pp. 3460-3465. https://doi.org/10.1073/pnas.0611660104
Kano, Mitsunobu ; Bae, Younsoo ; Iwata, Caname ; Morishita, Yasuyuki ; Yashiro, Masakazu ; Oka, Masako ; Fujii, Tomoko ; Komuro, Akiyoshi ; Kiyono, Kunihiko ; Kaminishi, Michio ; Hirakawa, Kosei ; Ouchi, Yasuyoshi ; Nishiyama, Nobuhiro ; Kataoka, Kazunori ; Miyazono, Kohei. / Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. In: Proceedings of the National Academy of Sciences of the United States of America. 2007 ; Vol. 104, No. 9. pp. 3460-3465.
@article{cbf1c8e9bcb14bc68b141a20ef262e88,
title = "Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling",
abstract = "Transforming growth factor (TGF)-β plays a pivotal role in regulation of progression of cancer through effects on tumor microenvironment as well as on cancer cells. TGF-β inhibitors have recently been shown to prevent the growth and metastasis of certain cancers. However, there may be adverse effects caused by TGF-β signaling inhibition, including the induction of cancers by the repression of TGF-β-mediated growth inhibition. Here, we present an application of a short-acting, small-molecule TGF-β type I receptor (TβR-I) inhibitor at a low dose in treating several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer, characterized by hypovascularity and thick fibrosis in tumor microenvironments. Low-dose TβR-I inhibitor altered neither TGF-β signaling in cancer cells nor the amount of fibrotic components. However, it decreased pericyte coverage of the endothelium without reducing endothelial area specifically in tumor neovasculature and promoted accumulation of macromolecules, including anticancer nanocarriers, in the tumors. Compared with the absence of TβR-I inhibitor, anticancer nanocarriers exhibited potent growth-inhibitory effects on these cancers in the presence of TβR-I inhibitor. The use of TβR-I inhibitor combined with nanocarriers may thus be of significant clinical and practical importance in treating intractable solid cancers.",
keywords = "Angiogenesis, Gastric cancer, Molecular targeting therapy, Pancreatic cancer",
author = "Mitsunobu Kano and Younsoo Bae and Caname Iwata and Yasuyuki Morishita and Masakazu Yashiro and Masako Oka and Tomoko Fujii and Akiyoshi Komuro and Kunihiko Kiyono and Michio Kaminishi and Kosei Hirakawa and Yasuyoshi Ouchi and Nobuhiro Nishiyama and Kazunori Kataoka and Kohei Miyazono",
year = "2007",
month = "2",
day = "27",
doi = "10.1073/pnas.0611660104",
language = "English",
volume = "104",
pages = "3460--3465",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "9",

}

TY - JOUR

T1 - Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling

AU - Kano, Mitsunobu

AU - Bae, Younsoo

AU - Iwata, Caname

AU - Morishita, Yasuyuki

AU - Yashiro, Masakazu

AU - Oka, Masako

AU - Fujii, Tomoko

AU - Komuro, Akiyoshi

AU - Kiyono, Kunihiko

AU - Kaminishi, Michio

AU - Hirakawa, Kosei

AU - Ouchi, Yasuyoshi

AU - Nishiyama, Nobuhiro

AU - Kataoka, Kazunori

AU - Miyazono, Kohei

PY - 2007/2/27

Y1 - 2007/2/27

N2 - Transforming growth factor (TGF)-β plays a pivotal role in regulation of progression of cancer through effects on tumor microenvironment as well as on cancer cells. TGF-β inhibitors have recently been shown to prevent the growth and metastasis of certain cancers. However, there may be adverse effects caused by TGF-β signaling inhibition, including the induction of cancers by the repression of TGF-β-mediated growth inhibition. Here, we present an application of a short-acting, small-molecule TGF-β type I receptor (TβR-I) inhibitor at a low dose in treating several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer, characterized by hypovascularity and thick fibrosis in tumor microenvironments. Low-dose TβR-I inhibitor altered neither TGF-β signaling in cancer cells nor the amount of fibrotic components. However, it decreased pericyte coverage of the endothelium without reducing endothelial area specifically in tumor neovasculature and promoted accumulation of macromolecules, including anticancer nanocarriers, in the tumors. Compared with the absence of TβR-I inhibitor, anticancer nanocarriers exhibited potent growth-inhibitory effects on these cancers in the presence of TβR-I inhibitor. The use of TβR-I inhibitor combined with nanocarriers may thus be of significant clinical and practical importance in treating intractable solid cancers.

AB - Transforming growth factor (TGF)-β plays a pivotal role in regulation of progression of cancer through effects on tumor microenvironment as well as on cancer cells. TGF-β inhibitors have recently been shown to prevent the growth and metastasis of certain cancers. However, there may be adverse effects caused by TGF-β signaling inhibition, including the induction of cancers by the repression of TGF-β-mediated growth inhibition. Here, we present an application of a short-acting, small-molecule TGF-β type I receptor (TβR-I) inhibitor at a low dose in treating several experimental intractable solid tumors, including pancreatic adenocarcinoma and diffuse-type gastric cancer, characterized by hypovascularity and thick fibrosis in tumor microenvironments. Low-dose TβR-I inhibitor altered neither TGF-β signaling in cancer cells nor the amount of fibrotic components. However, it decreased pericyte coverage of the endothelium without reducing endothelial area specifically in tumor neovasculature and promoted accumulation of macromolecules, including anticancer nanocarriers, in the tumors. Compared with the absence of TβR-I inhibitor, anticancer nanocarriers exhibited potent growth-inhibitory effects on these cancers in the presence of TβR-I inhibitor. The use of TβR-I inhibitor combined with nanocarriers may thus be of significant clinical and practical importance in treating intractable solid cancers.

KW - Angiogenesis

KW - Gastric cancer

KW - Molecular targeting therapy

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=33847635618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33847635618&partnerID=8YFLogxK

U2 - 10.1073/pnas.0611660104

DO - 10.1073/pnas.0611660104

M3 - Article

C2 - 17307870

AN - SCOPUS:33847635618

VL - 104

SP - 3460

EP - 3465

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 9

ER -